Some Value Available in High Octane Healthcare ETF

Healthcare innovators, including genomics companies, are rarely inexpensive in equity market terms. Often, rich multiples are simply the cost of admission that investors have to pay to access a high-growth parts of the healthcare sector. However, there are times when some biotechnology and genomics...